What is Semax?
Semax is a synthetic peptide — a short chain of seven amino acids (a heptapeptide), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was engineered in Russia from a natural fragment of adrenocorticotropic hormone (ACTH), the part known as ACTH(4-10). Researchers took that hormone fragment and added a Pro-Gly-Pro "tail" to it. That small change does two things: it makes the peptide more stable so the body does not break it down as quickly, and it strips away the hormone-stimulating activity of the original ACTH fragment, so Semax is not meant to drive cortisol release.
The result is a compound studied mainly for the brain rather than for hormones. It is best known in two roles: as a neuroprotective agent (used in Russia around stroke) and as a "nootropic," a loosely defined category of substances claimed to support attention, memory, or mental stamina. Because peptides like this are poorly absorbed if swallowed, Semax is given as nasal drops or spray, and sometimes by injection — not as a pill.
It is important to set expectations honestly from the start. Semax is real and has a genuine history of medical use, but that history is almost entirely Russian, and the rigorous, large-scale Western trials that anchor most FDA-approved drugs largely do not exist for it. The sections below separate what is established from what is still uncertain.
Where is Semax actually approved?
This is the single most important fact about Semax, and it is widely blurred online. Semax is approved and used in Russia. It appears on the Russian Federation's List of Vital and Essential Drugs, and in Russian medical practice it is used intranasally for indications such as stroke and transient ischemic attack, memory and cognitive disorders, and optic-nerve conditions. In other words, in its home country it is a registered medicine, not an underground compound.
Outside Russia, the picture is completely different. Semax has not been evaluated, approved, or marketed in most other countries. In the United States it is not FDA-approved for any use and is unscheduled — meaning it is neither an approved drug nor a controlled substance. The European Medicines Agency has not approved it either. So a product sold under the name "Semax" in the US is not an approved medicine and is typically labeled as a research chemical not intended for human consumption, which places it outside the regulatory standards that govern an approved drug's identity, purity, and sterility.
The takeaway: "approved" is true in Russia and false in the United States, and those two facts are not interchangeable. Russian registration does not transfer any approval, quality assurance, or prescribing authority to the US — it simply tells you the compound has a real medical history in one country.
Is there an official dose?
Not in the United States. Because Semax has never been reviewed or approved by the FDA, there is no FDA-validated dose, no approved prescribing information, and no official US dosing chart for a clinician to follow. Any number you find online describing a "Semax dose" is, at best, a description of what was used in Russian clinical practice or in a research study — not an approved instruction, and not advice for an individual.
For information only, and to be precise about what the Russian usage looks like: Semax is formulated there as an intranasal aqueous solution, commonly at a 0.1% or 1% concentration, delivered as drops into the nostrils. The 1% preparation has been used in the higher-dose, stroke-recovery context, while the lower 0.1% concentration is the one associated with cognitive or "nootropic" use. Russian protocols typically describe short treatment courses rather than indefinite use. These figures describe a foreign clinical practice; they are not a recommendation, a starting point, or a target for anyone reading this page.
The honest framing is that translating a Russian dosing convention into a personal regimen is exactly the kind of decision that should not be made from an article. It belongs to a licensed clinician who can weigh the (limited) evidence, the product's unverified quality outside Russia, and a specific person's health history. This guide deliberately does not provide a dosing chart for self-directed use.
What does the evidence really show?
The most consistent mechanistic finding for Semax comes from animal studies of neurotrophins — the proteins that keep neurons healthy and support their ability to form new connections. In rats, a single dose of Semax raises the expression of brain-derived neurotrophic factor (BDNF) across several brain regions. After an induced stroke in rodents, Semax has been shown to switch on transcription of neurotrophins and their receptor genes in the cortex, which researchers propose as part of why it appears neuroprotective in Russian clinical use.
There is also evidence that Semax reaches beyond neurotrophins. A genome-wide study in a rat stroke model found that the gene-expression process most strongly affected by Semax was the immune response, alongside changes in vascular-related genes — pointing to anti-inflammatory and blood-vessel effects as additional proposed mechanisms. Separately, Semax is described as rapidly activating dopaminergic and serotonergic systems in the brain, which is the kind of effect often invoked to explain its "nootropic" reputation. These are biologically interesting and reasonably well documented in animals.
But here is the limit that honesty requires stating plainly: the great majority of this evidence is preclinical (rodent) or comes from Russian clinical studies that, as a body, would not meet the size, design, and independent-audit standards expected for FDA approval. There is no large, Western, placebo-controlled randomized trial establishing that Semax produces a defined cognitive or recovery benefit in people. So the fair summary is "promising mechanisms and a real Russian clinical track record, but an evidence base that is limited and not Western-validated" — not "proven."
| Study / model | Finding | Evidence quality |
|---|---|---|
| Dolotov, Dokl Biol Sci 2003 (rat) | A single dose of Semax raised BDNF expression across several brain regions. | Animal (rat) |
| Dmitrieva, Cell Mol Neurobiol 2010 (rat, stroke) | Activated transcription of neurotrophins and their receptor genes after cerebral ischemia. | Animal (rat, stroke) |
| Medvedeva, BMC Genomics 2014 (rat, genome-wide) | Immune-response genes were most strongly affected, alongside vascular-related changes. | Animal (rat) |
| Eremin, Neurochem Res 2005 (rodent) | Serotonin turnover rose up to ~180% in the striatum; dopamine release enhanced. | Animal (rodent) |
| Gusev, ischemic stroke 2018 (human) | Raised plasma BDNF and improved functional/motor recovery — but a non-randomized study. | Human — non-randomized (Russian) |
| Regulatory status | Approved and on the essential-medicines list in Russia; NOT FDA-approved and unscheduled in the US. | Regulatory (approved only in Russia) |
How does Semax affect brain chemistry?
Beyond neurotrophins, Semax has measurable effects on the brain's monoamine systems — the dopamine and serotonin signaling that shapes mood, motivation, and attention. In rats, Semax raised serotonin turnover in the striatum by up to roughly 180% within one to four hours of a dose, and it enhanced dopamine release when paired with a dopamine-releasing stimulant, alongside increased locomotor activity. Researchers point to this rapid activation of monoamine systems as a plausible part of why Semax earned its "nootropic" reputation for alertness and mental stamina, distinct from the slower, structural neurotrophin effects.
Two honest caveats belong right next to that finding. First, these are rodent measurements of brain chemistry, not demonstrations that a person becomes measurably sharper or more focused — a neurotransmitter shift in a rat striatum is a mechanism, not a proven human benefit. Second, "activates dopamine and serotonin systems" is exactly the kind of phrase marketing copy reaches for, because it sounds like a guaranteed mood-and-focus upgrade. The evidence supports the biochemistry; it does not support the promise. The distance between "changes monoamine signaling in animals" and "reliably improves cognition in healthy people" is the same gap this whole page keeps returning to.
Has Semax been studied in stroke patients?
Yes — and this is the strongest part of the human story, so it deserves a fair hearing alongside its limits. In Russian neurology, Semax has been used as an add-on in the rehabilitation of ischemic stroke. Clinical reports describe patients given Semax showing higher circulating BDNF levels that stayed elevated through the treatment period, together with faster functional recovery and better motor performance than comparison groups. That dovetails with the animal neurotrophin data and is a real reason Semax is taken seriously in its home country rather than dismissed.
But notice what these studies are and are not. The published reports are generally not large, randomized, double-blind, placebo-controlled trials — the design that shields a result from bias and from the placebo effect. Several are open-label or non-randomized comparisons, the kind of evidence that can suggest a benefit but cannot establish one to the standard a regulator like the FDA requires before calling a drug effective. So the accurate way to hold this is: there is genuine human clinical experience with Semax in stroke recovery in Russia, and it is encouraging — but "encouraging clinical experience" is a weaker claim than "proven in rigorous trials," and that difference matters enormously when the question is whether a compound actually works.
What are the risks, and the research-grade-purity unknown for US buyers?
Within its approved Russian use, Semax has generally been described as well-tolerated, and the Pro-Gly-Pro modification was specifically designed to avoid the adrenal/hormonal stimulation of the parent ACTH fragment. But "generally well-tolerated in Russian practice" is not the same as a fully characterized safety profile: there is no large, long-term, independently audited Western safety dataset, and the question of repeated use over long periods has not been resolved to that standard.
For anyone outside Russia, there is a second risk that has nothing to do with the molecule itself and everything to do with the product. A "Semax" vial bought in the US is not an FDA-approved medicine; it is typically sold research-use-only and labeled not for human consumption. That means no regulated manufacturing, no guarantee of identity, no verified peptide purity, no confirmed dose accuracy, and — critically for anything put into the nose or injected — no assured sterility or endotoxin control. Contamination and mislabeling are real, documented categories of risk for research-grade peptides obtained outside an approved supply chain, independent of whatever Semax may or may not do.
In short, a US buyer faces two stacked unknowns at once: an evidence base that is limited and largely non-Western, and a supply whose quality cannot be assumed. Both belong in any honest accounting of the risk.
Who should you ask?
A licensed clinician — not an article, a forum, or a vendor. The relevant questions here are genuinely medical: whether Semax has any place at all given a person's health history, how to weigh a largely non-Western evidence base, what an unverified research-grade product actually contains, and how any of that interacts with other conditions or medications. Those are judgments a qualified physician is equipped to make and an internet page is not.
It is also worth knowing that the regulatory landscape for research peptides is in motion, and a clinician is the right person to interpret what any change means for an individual. The bottom line does not move, though: today, Semax is approved in Russia, not in the United States, its evidence is limited by Western standards, and nothing on this page is a recommendation to use it.
Tracking a clinician-directed protocol on PeptidePanel
PeptidePanel does not sell, source, supply, endorse, or prescribe Semax or any other compound, and nothing on this page is medical advice. The educational nature of this content is not an endorsement of using Semax, particularly outside the country where it is approved. The decision to include any compound in a protocol — and at what dose, route, and duration — belongs to a licensed clinician who can weigh the available evidence against an individual's full medical history.
If a clinician has set a protocol and tracking is in scope, PeptidePanel's logging tools provide a neutral, timestamped record of what was administered and of any biomarker or symptom changes observed over time. That record exists to support continuity of care between a patient and their clinician — not to guide self-directed use.